Subscribe to RSS
DOI: 10.1055/a-2685-2169
Clinical Impact of the PDA and Its Management on Outcomes of Preterm Infants with NEC: A Review
Funding Information P.M.G. is partially supported by the NIGMS of the NIH under award number U54GM115428. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Abstract
Necrotizing enterocolitis (NEC) is one of the most common gastrointestinal emergencies in preterm infants. The pathogenesis of NEC is not clearly established and multifactorial. Preterm infants are at increased risk for NEC because of intestinal immaturity, resulting in potential mucosal injury. Circulatory instability has been proposed as a key indicator for ischemic insult to the gut, leading to NEC. With the increased incidence of patent ductus arteriosus (PDA) in preterm infants less than 32 weeks and in babies with birth weight less than 1,500 g, several studies propose an association of NEC with a hemodynamically significant PDA. This review provides an extensive literature search for NEC and PDA in the PUBMED database. In this study, we will review the pathogenesis of NEC and the relationship between PDA and NEC. We will also explore the different treatment options for PDA and their relationship to the incidence of NEC. While earlier diagnosis and aggressive treatment of NEC have improved the outcomes, the disease still accounts for 10% of deaths in infants in the neonatal intensive care unit. With resuscitation of increasingly earlier gestational age infants, the incidence of both hemodynamically significant PDA and NEC is rising, denoting the importance of understanding the inter-relationship of these two pathophysiological processes.
Key Points
-
• The relationship between PDA and NEC is studied.
-
• The pathophysiology of NEC is described.
-
• Propose future directions for the use of advanced technologies to identify at-risk preterm infants.
Contributors' Statement
P.M.G. and V.G. designed the study. V.G., P.M.G., N.J., P.P., R.J.R., and J.S. wrote the article. All the authors approved the manuscript.
Publication History
Received: 06 June 2025
Accepted: 18 August 2025
Accepted Manuscript online:
19 August 2025
Article published online:
29 August 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Lau PE, Cruz SM, Ocampo EC. et al. Necrotizing enterocolitis in patients with congenital heart disease: a single center experience. J Pediatr Surg 2018; 53 (05) 914-917
- 2 McElhinney DB, Hedrick HL, Bush DM. et al. Necrotizing enterocolitis in neonates with congenital heart disease: risk factors and outcomes. Pediatrics 2000; 106 (05) 1080-1087
- 3 Kochanek KD, Xu J, Arias E. Mortality in the United States, 2019. NCHS Data Brief 2020; (395) 1-8
- 4 Han SM, Hong CR, Knell J. et al. Trends in incidence and outcomes of necrotizing enterocolitis over the last 12 years: a multicenter cohort analysis. J Pediatr Surg 2020; 55 (06) 998-1001
- 5 Holman RC, Stoll BJ, Curns AT, Yorita KL, Steiner CA, Schonberger LB. Necrotising enterocolitis hospitalisations among neonates in the United States. Paediatr Perinat Epidemiol 2006; 20 (06) 498-506
- 6 Horbar JD, Badger GJ, Carpenter JH. et al; Members of the Vermont Oxford Network. Trends in mortality and morbidity for very low birth weight infants, 1991-1999. Pediatrics 2002; 110 (1 Pt 1): 143-151
- 7 Tian B, Xu X, Li L. et al. Epigenetic insights into necrotizing enterocolitis: unraveling methylation-regulated biomarkers. Inflammation 2025; 48 (01) 236-253
- 8 Hu X, Liang H, Li F. et al. Necrotizing enterocolitis: current understanding of the prevention and management. Pediatr Surg Int 2024; 40 (01) 32
- 9 Gipson DR, Chang AL, Lure AC. et al. Reassessing acquired neonatal intestinal diseases using unsupervised machine learning. Pediatr Res 2024; 96 (01) 165-171
- 10 Zani A, Pierro A. Necrotizing enterocolitis: controversies and challenges. F1000 Res 2015; 4: 4
- 11 Rees CM, Eaton S, Pierro A. National prospective surveillance study of necrotizing enterocolitis in neonatal intensive care units. J Pediatr Surg 2010; 45 (07) 1391-1397
- 12 Yee WH, Soraisham AS, Shah VS, Aziz K, Yoon W, Lee SK. Canadian Neonatal Network. Incidence and timing of presentation of necrotizing enterocolitis in preterm infants. Pediatrics 2012; 129 (02) e298-e304
- 13 Stoll BJ, Hansen NI, Bell EF. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314 (10) 1039-1051
- 14 Hull MA, Fisher JG, Gutierrez IM. et al. Mortality and management of surgical necrotizing enterocolitis in very low birth weight neonates: a prospective cohort study. J Am Coll Surg 2014; 218 (06) 1148-1155
- 15 Jones IH, Hall NJ. Contemporary outcomes for infants with necrotizing enterocolitis-a systematic review. J Pediatr 2020; 220: 86-92.e3
- 16 Barker CA, Crowley TA. The infancy of the CVMA: 1948-1967. Can Vet J 1998; 39 (03) 145-147
- 17 Chong C, van Druten J, Briars G. et al. Neonates living with enterostomy following necrotising enterocolitis are at high risk of becoming severely underweight. Eur J Pediatr 2019; 178 (12) 1875-1881
- 18 Hintz SR, Kendrick DE, Stoll BJ. et al; NICHD Neonatal Research Network. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics 2005; 115 (03) 696-703
- 19 Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis. Arch Dis Child Fetal Neonatal Ed 2007; 92 (03) F193-F198
- 20 Schulzke SM, Deshpande GC, Patole SK. Neurodevelopmental outcomes of very low-birth-weight infants with necrotizing enterocolitis: a systematic review of observational studies. Arch Pediatr Adolesc Med 2007; 161 (06) 583-590
- 21 Matei A, Montalva L, Goodbaum A, Lauriti G, Zani A. Neurodevelopmental impairment in necrotising enterocolitis survivors: systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2020; 105 (04) 432-439
- 22 Rallis D, Saliakellis E, Kaselas C. et al. Is there an association between necrotizing enterocolitis in premature neonates and functional gastrointestinal disorders later in childhood?. Neurogastroenterol Motil 2022; 34 (03) e14222
- 23 Lai KC, Lorch SA. Healthcare costs of major morbidities associated with prematurity in US children's hospitals. J Pediatr 2023; 256: 53-62.e4
- 24 Mowitz ME, Dukhovny D, Zupancic JAF. The cost of necrotizing enterocolitis in premature infants. Semin Fetal Neonatal Med 2018; 23 (06) 416-419
- 25 Ballance WA, Dahms BB, Shenker N, Kliegman RM. Pathology of neonatal necrotizing enterocolitis: a ten-year experience. J Pediatr 1990; 117 (1 Pt 2): S6-S13
- 26 Elgin TG, Kern SL, McElroy SJ. Development of the neonatal intestinal microbiome and its association with necrotizing enterocolitis. Clin Ther 2016; 38 (04) 706-715
- 27 Israel EJ. Neonatal necrotizing enterocolitis, a disease of the immature intestinal mucosal barrier. Acta Paediatr Suppl 1994; 396: 27-32
- 28 Crissinger KD, Granger DN. Mucosal injury induced by ischemia and reperfusion in the piglet intestine: influences of age and feeding. Gastroenterology 1989; 97 (04) 920-926
- 29 Rozee KR, Cooper D, Lam K, Costerton JW. Microbial flora of the mouse ileum mucous layer and epithelial surface. Appl Environ Microbiol 1982; 43 (06) 1451-1463
- 30 Deitch EA. Role of bacterial translocation in necrotizing enterocolitis. Acta Paediatr Suppl 1994; 396: 33-36
- 31 Su Y, Xu RH, Guo LY. et al. Risk factors for necrotizing enterocolitis in neonates: a meta-analysis. Front Pediatr 2023; 10: 1079894
- 32 Tao HK, Tang Q, Hei MY, Yu B. [Meta-analysis of post-transfusion necrotizing enterocolitis in neonates]. Zhonghua Er Ke Za Zhi 2013; 51 (05) 336-339
- 33 Kalteren WS, Bos AF, van Oeveren W, Hulscher JBF, Kooi EMW. Neonatal anemia relates to intestinal injury in preterm infants. Pediatr Res 2022; 91 (06) 1452-1458
- 34 Nagasawa H, Hamada C, Wakabayashi M, Nakagawa Y, Nomura S, Kohno Y. Time to spontaneous ductus arteriosus closure in full-term neonates. Open Heart 2016; 3 (01) e000413
- 35 Dice JE, Bhatia J. Patent ductus arteriosus: an overview. J Pediatr Pharmacol Ther 2007; 12 (03) 138-146
- 36 Fay FS, Cooke PH. Guinea pig ductus arteriosus. II. Irreversible closure after birth. Am J Physiol 1972; 222 (04) 841-849
- 37 Clyman RI, Waleh N, Black SM, Riemer RK, Mauray F, Chen YQ. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation, oxygen tension, and vasa vasorum. Pediatr Res 1998; 43 (05) 633-644
- 38 Clyman RI, Chan CY, Mauray F. et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res 1999; 45 (01) 19-29
- 39 Clyman RI, Mauray F, Roman C, Heymann MA, Payne B. Effect of gestational age on ductus arteriosus response to circulating prostaglandin E2. J Pediatr 1983; 102 (06) 907-911
- 40 Lemons JA, Bauer CR, Oh W. et al; NICHD Neonatal Research Network. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. Pediatrics 2001; 107 (01) E1
- 41 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117 (04) 1113-1121
- 42 Kindler A, Seipolt B, Heilmann A, Range U, Rüdiger M, Hofmann SR. Development of a diagnostic clinical score for hemodynamically significant patent ductus arteriosus. Front Pediatr 2017; 5: 280
- 43 Green CA, Westreich D, Laughon MM. et al. Association of chorioamnionitis and patent ductus arteriosus in a national U.S. cohort. J Perinatol 2021; 41 (01) 119-125
- 44 Terrin G, Di Chiara M, Boscarino G. et al. Morbidity associated with patent ductus arteriosus in preterm newborns: a retrospective case-control study. Ital J Pediatr 2021; 47 (01) 9
- 45 Khanafer-Larocque I, Soraisham A, Stritzke A. et al. Intraventricular hemorrhage: risk factors and association with patent ductus arteriosus treatment in extremely preterm neonates. Front Pediatr 2019; 7: 408
- 46 Gentle SJ, Travers CP, Clark M, Carlo WA, Ambalavanan N. Patent ductus arteriosus and development of bronchopulmonary dysplasia-associated pulmonary hypertension. Am J Respir Crit Care Med 2023; 207 (07) 921-928
- 47 Garland J, Buck R, Weinberg M. Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study. Pediatrics 1994; 94 (05) 719-723
- 48 Kordasz M, Racine M, Szavay P. et al. Risk factors for mortality in preterm infants with necrotizing enterocolitis: a retrospective multicenter analysis. Eur J Pediatr 2022; 181 (03) 933-939
- 49 Guillet R, Selewski DT, Griffin R, Rastogi S, Askenazi DJ, D'Angio CT. Neonatal Kidney Collaborative. Relationship of patent ductus arteriosus management with neonatal AKI. J Perinatol 2021; 41 (06) 1441-1447
- 50 Zhao S, Jiang H, Miao Y. et al. Factors influencing necrotizing enterocolitis in premature infants in China: a systematic review and meta-analysis. BMC Pediatr 2024; 24 (01) 148
- 51 Surak A, Sidhu A, Ting JY. Should we “eliminate” PDA shunt in preterm infants? A narrative review. Front Pediatr 2024; 12: 1257694
- 52 McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92 (06) F424-F427
- 53 Fink D, El-Khuffash A, McNamara PJ, Nitzan I, Hammerman C. Tale of two patent ductus arteriosus severity scores: similarities and differences. Am J Perinatol 2018; 35 (01) 55-58
- 54 Sankar MN, Bhombal S, Benitz WE. PDA: to treat or not to treat. Congenit Heart Dis 2019; 14 (01) 46-51
- 55 Buvaneswarran S, Wong YL, Liang S, Quek SC, Lee J. Active treatment vs expectant management of patent ductus arteriosus in preterm infants: a meta-analysis. JAMA Pediatr 2025; 179 (08) 877-885
- 56 Saldeño YP, Favareto V, Mirpuri J. Prolonged persistent patent ductus arteriosus: potential perdurable anomalies in premature infants. J Perinatol 2012; 32 (12) 953-958
- 57 Kessler U, Schulte F, Cholewa D. et al. Outcome in neonates with necrotizing enterocolitis and patent ductus arteriosus. World J Pediatr 2016; 12 (01) 55-59
- 58 Clyman RI, Liebowitz M, Kaempf J. et al; PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators. PDA-tolerate trial: an exploratory randomized controlled trial of treatment of moderate-to-large patent ductus arteriosus at 1 week of age. J Pediatr 2019; 205: 41-48.e6
- 59 Martinussen M, Brubakk AM, Vik T, Yao AC. Mesenteric blood flow velocity and its relation to transitional circulatory adaptation in appropriate for gestational age preterm infants. Pediatr Res 1996; 39 (02) 275-280
- 60 Petrova A, Bhatt M, Mehta R. Regional tissue oxygenation in preterm born infants in association with echocardiographically significant patent ductus arteriosus. J Perinatol 2011; 31 (07) 460-464
- 61 Freeman-Ladd M, Cohen JB, Carver JD, Huhta JC. The hemodynamic effects of neonatal patent ductus arteriosus shunting on superior mesenteric artery blood flow. J Perinatol 2005; 25 (07) 459-462
- 62 McCurnin D, Clyman RI. Effects of a patent ductus arteriosus on postprandial mesenteric perfusion in premature baboons. Pediatrics 2008; 122 (06) e1262-e1267
- 63 Diez S, Tielesch L, Weiss C, Halbfass J, Müller H, Besendörfer M. Clinical characteristics of necrotizing enterocolitis in preterm patients with and without persistent ductus arteriosus and in patients with congenital heart disease. Front Pediatr 2020; 8: 257
- 64 Lemmers PM, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 2008; 121 (01) 142-147
- 65 Bhatt M, Petrova A, Mehta R. Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation?. Pediatr Cardiol 2012; 33 (08) 1307-1314
- 66 Martini S, Corvaglia L, Aceti A, Vitali F, Faldella G, Galletti S. Effect of patent ductus arteriosus on splanchnic oxygenation at enteral feeding introduction in very preterm infants. J Pediatr Gastroenterol Nutr 2019; 69 (04) 493-497
- 67 Lindberg TP, Caimano MJ, Hagadorn JI. et al. Preterm infant gut microbial patterns related to the development of necrotizing enterocolitis. J Matern Fetal Neonatal Med 2020; 33 (03) 349-358
- 68 Li F, Hooi SL, Choo YM. et al. Progression of gut microbiome in preterm infants during the first three months. Sci Rep 2025; 15 (01) 12104
- 69 Sellmer A, Henriksen TB, Palmfeldt J. et al. The patent ductus arteriosus in extremely preterm neonates is more than a hemodynamic challenge: new molecular insights. Biomolecules 2022; 12 (09) 1179
- 70 Dani C, Pratesi S. Patent ductus arteriosus and oxidative stress in preterm infants: a narrative review. Transl Pediatr 2020; 9 (06) 835-839
- 71 Dollberg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr 2005; 40 (02) 184-188
- 72 Hundscheid T, Onland W, Kooi EMW. et al; BeNeDuctus Trial Investigators. Expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med 2023; 388 (11) 980-990
- 73 El Sherif DF, El Raggal NM, Nasef MW, Saleh GA, Youssef NH, Metwally MH. Oral ibuprofen versus placebo in closure of patent ductus arteriosus in preterm neonates, a randomized control trial. J Neonatal Perinatal Med 2024; 17 (06) 810-820
- 74 Yadav S, Agarwal S, Maria A. et al. Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial. Pediatr Cardiol 2014; 35 (05) 824-830
- 75 Hammerman C, Shchors I, Jacobson S. et al. Ibuprofen versus continuous indomethacin in premature neonates with patent ductus arteriosus: is the difference in the mode of administration?. Pediatr Res 2008; 64 (03) 291-297
- 76 Tammela O, Ojala R, Iivainen T. et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr 1999; 134 (05) 552-557
- 77 Rhodes PG, Ferguson MG, Reddy NS, Joransen JA, Gibson J. Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. Eur J Pediatr 1988; 147 (05) 481-484
- 78 Dash SK, Kabra NS, Avasthi BS, Sharma SR, Padhi P, Ahmed J. Enteral paracetamol or intravenous indomethacin for closure of patent ductus arteriosus in preterm neonates: a randomized controlled trial. Indian Pediatr 2015; 52 (07) 573-578
- 79 Chotigeat U, Jirapapa K, Layangkool T. A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. J Med Assoc Thai 2003; 86 (Suppl. 03) S563-S569
- 80 Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001; 138 (02) 205-211
- 81 Grosfeld JL, Chaet M, Molinari F. et al. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg 1996; 224 (03) 350-355 , discussion 355–357
- 82 Palder SB, Schwartz MZ, Tyson KR, Marr CC. Management of patent ductus arteriosus: a comparison of operative v pharmacologic treatment. J Pediatr Surg 1987; 22 (12) 1171-1174
- 83 Alexander F, Chiu L, Kroh M, Hammel J, Moore J. Analysis of outcome in 298 extremely low-birth-weight infants with patent ductus arteriosus. J Pediatr Surg 2009; 44 (01) 112-117
- 84 Fujii AM, Brown E, Mirochnick M, O'Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol 2002; 22 (07) 535-540
- 85 O'Donovan DJ, Baetiong A, Adams K. et al. Necrotizing enterocolitis and gastrointestinal complications after indomethacin therapy and surgical ligation in premature infants with patent ductus arteriosus. J Perinatol 2003; 23 (04) 286-290
- 86 Sood BG, Lulic-Botica M, Holzhausen KA. et al. The risk of necrotizing enterocolitis after indomethacin tocolysis. Pediatrics 2011; 128 (01) e54-e62
- 87 Little DC, Pratt TC, Blalock SE, Krauss DR, Cooney DR, Custer MD. Patent ductus arteriosus in micropreemies and full-term infants: the relative merits of surgical ligation versus indomethacin treatment. J Pediatr Surg 2003; 38 (03) 492-496
- 88 Koehne PS, Bein G, Alexi-Meskhishvili V, Weng Y, Bührer C, Obladen M. Patent ductus arteriosus in very low birthweight infants: complications of pharmacological and surgical treatment. J Perinat Med 2001; 29 (04) 327-334
- 89 Mitra S, Florez ID, Tamayo ME. et al. Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. JAMA 2018; 319 (12) 1221-1238
- 90 Huang X, Wang F, Wang K. Paracetamol versus ibuprofen for the treatment of patent ductus arteriosus in preterm neonates: a meta-analysis of randomized controlled trials. J Matern Fetal Neonatal Med 2018; 31 (16) 2216-2222
- 91 Khuwuthyakorn V, Jatuwattana C, Silvilairat S, Tantiprapha W. Oral indomethacin versus oral ibuprofen for treatment of patent ductus arteriosus: a randomised controlled study in very low-birthweight infants. Paediatr Int Child Health 2018; 38 (03) 187-192
- 92 Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev 2020; 2 (02) CD003481
- 93 Mitra S, Scrivens A, von Kursell AM, Disher T. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev 2020; 12 (12) CD013278
- 94 Yee WH, Scotland J. Evidence-based Practice for Improving Quality (EPIQ) Evidence Review Group. Does primary surgical closure of the patent ductus arteriosus in infants <1500. g or ≤32 weeks' gestation reduce the incidence of necrotizing enterocolitis?. Paediatr Child Health 2012; 17 (03) 125-128
- 95 Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2023; 4 (04) CD013588
- 96 van de Watering AE, van Rossem SAM, Baron Toaldo M. et al. Doppler ultrasonographic assessment of abdominal aortic flow to evaluate the hemodynamic relevance of left-to-right shunting patent ductus arteriosus in dogs. Animals (Basel) 2024; 14 (10) 1404
- 97 Mishra V, Mathur AA, Mohamed S, Maheshwari A. Role of near-infrared spectroscopy in the diagnosis and assessment of necrotizing enterocolitis. Newborn (Clarksville) 2022; 1 (01) 177-181
- 98 Zamora IJ, Stoll B, Ethun CG. et al. Low abdominal NIRS values and elevated plasma intestinal fatty acid-binding protein in a premature piglet model of necrotizing enterocolitis. PLoS One 2015; 10 (06) e0125437
- 99 Martini S, Corvaglia L. Splanchnic NIRS monitoring in neonatal care: rationale, current applications and future perspectives. J Perinatol 2018; 38 (05) 431-443
- 100 Cortez J, Gupta M, Amaram A, Pizzino J, Sawhney M, Sood BG. Noninvasive evaluation of splanchnic tissue oxygenation using near-infrared spectroscopy in preterm neonates. J Matern Fetal Neonatal Med 2011; 24 (04) 574-582
- 101 van der Heide M, Hulscher JBF, Bos AF, Kooi EMW. Near-infrared spectroscopy as a diagnostic tool for necrotizing enterocolitis in preterm infants. Pediatr Res 2021; 90 (01) 148-155
- 102 Fortune PM, Wagstaff M, Petros AJ. Cerebro-splanchnic oxygenation ratio (CSOR) using near infrared spectroscopy may be able to predict splanchnic ischaemia in neonates. Intensive Care Med 2001; 27 (08) 1401-1407
- 103 Navikiene J, Virsilas E, Vankeviciene R, Liubsys A, Jankauskiene A. Brain and renal oxygenation measured by NIRS related to patent ductus arteriosus in preterm infants: a prospective observational study. BMC Pediatr 2021; 21 (01) 559
- 104 Neu J, Walker WA. Necrotizing enterocolitis. N Engl J Med 2011; 364 (03) 255-264
- 105 Garg PM. Surgical NEC-associated cerebellar underdevelopment and PDA: Call for close monitoring and action. J Neonatal Perinatal Med 2025; 18 (02) 165-166
- 106 Krueger E, Mellander M, Bratton D, Cotton R. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr 1987; 111 (05) 749-754
- 107 Evans P, O'Reilly D, Flyer JN, Soll R, Mitra S. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev 2021; 1 (01) CD013133
- 108 Jansen EJS, Hundscheid T, Onland W, Kooi EMW, Andriessen P, de Boode WP. Factors associated with benefit of treatment of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. Front Pediatr 2021; 9: 626262
- 109 Thomas RL, Parker GC, Van Overmeire B, Aranda JV. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005; 164 (03) 135-140